Jacobs Levy Equity Management Inc. Has $6.46 Million Holdings in DaVita Inc. (NYSE:DVA)

Jacobs Levy Equity Management Inc. reduced its position in DaVita Inc. (NYSE:DVA - Free Report) by 29.3% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 39,418 shares of the company's stock after selling 16,339 shares during the period. Jacobs Levy Equity Management Inc.'s holdings in DaVita were worth $6,462,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Transcendent Capital Group LLC acquired a new stake in shares of DaVita in the 3rd quarter valued at $25,000. Blue Trust Inc. increased its stake in shares of DaVita by 58.6% in the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company's stock valued at $29,000 after buying an additional 78 shares during the period. Family Firm Inc. acquired a new stake in shares of DaVita in the 2nd quarter valued at $43,000. Friedenthal Financial acquired a new stake in shares of DaVita in the 2nd quarter valued at $48,000. Finally, Point72 Hong Kong Ltd bought a new position in shares of DaVita in the 2nd quarter worth $68,000. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Trading Down 0.7 %

DVA stock traded down $1.14 during midday trading on Friday, hitting $160.23. 506,736 shares of the company's stock were exchanged, compared to its average volume of 814,629. The stock's fifty day moving average price is $158.63 and its 200-day moving average price is $150.01. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37. The company has a market cap of $13.14 billion, a PE ratio of 17.44, a price-to-earnings-growth ratio of 0.93 and a beta of 0.90. DaVita Inc. has a one year low of $103.40 and a one year high of $169.51.

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing the consensus estimate of $2.76 by ($0.17). The business had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. The business's revenue was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.85 earnings per share. Research analysts predict that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on DVA shares. Truist Financial raised their price target on DaVita from $165.00 to $175.00 and gave the stock a "hold" rating in a research report on Monday, October 7th. UBS Group raised their price target on DaVita from $169.00 to $175.00 and gave the stock a "buy" rating in a research report on Thursday, August 8th. Finally, Barclays raised their price target on DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $161.80.

Insider Activity

In related news, CEO Javier Rodriguez sold 50,000 shares of DaVita stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the sale, the chief executive officer now owns 837,835 shares of the company's stock, valued at approximately $138,284,666.75. The trade was a 5.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 2.00% of the company's stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.